MOCHIDA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,115 JPY | +0.32% |
|
-0.48% | -4.74% |
| Sales 2024 * | 102B 660M | Sales 2025 * | 106B 686M | Capitalization | 110B 713M |
|---|---|---|---|---|---|
| Net income 2024 * | 4.4B 28.49M | Net income 2025 * | 5.9B 38.2M | EV / Sales 2024 * | 0.46 x |
| Net cash position 2024 * | 62.97B 408M | Net cash position 2025 * | 64.14B 415M | EV / Sales 2025 * | 0.43 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
18.7
x | Employees | 1,529 |
| Yield 2024 * |
2.58% | Yield 2025 * |
2.58% | Free-Float | 53.94% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +0.32% | ||
| 1 week | -0.48% | ||
| Current month | -3.26% | ||
| 1 month | -4.89% | ||
| 3 months | -6.32% | ||
| 6 months | -4.45% | ||
| Current year | -4.74% |
1 week
3 105.00
3 165.00
1 month
3 085.003 315.00
Current year
3 055.003 430.00
1 year
3 055.003 745.00
3 years
3 025.004 075.00
5 years
3 025.005 380.00
10 years
2 985.006 110.00
| Managers | Title | Age | Since |
|---|---|---|---|
Naoyuki Mochida
PSD | President | 65 | 91-03-31 |
| Chief Administrative Officer | 61 | 17-05-31 | |
| Chief Tech/Sci/R&D Officer | 66 | 82-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Naoyuki Mochida
PSD | President | 65 | 91-03-31 |
Nana Otsuki
BRD | Director/Board Member | 59 | 21-06-28 |
Keiichi Sagisaka
BRD | Director/Board Member | 66 | 80-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 15 M€ | +4.35% | ||
| 0.02% | 4 M€ | +14.10% | ||
| 0.02% | 18 M€ | +16.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3,115 | +0.32% | 12 700 |
| 24-04-17 | 3,105 | -1.27% | 30,000 |
| 24-04-16 | 3,145 | -0.63% | 27,200 |
| 24-04-15 | 3,165 | 0.00% | 26,700 |
| 24-04-12 | 3,165 | +1.12% | 32,300 |
Delayed Quote Japan Exchange, April 18, 2024 at 02:00 am EDT
More quotes
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,105
JPY
Average target price
3,200
JPY
Spread / Average Target
+3.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.74% | 712M | |
| +28.79% | 676B | |
| +24.47% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +3.19% | 210B | |
| -0.25% | 204B | |
| -9.49% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- 4534 Stock
